CUE Q4 Preview – Ready For The Clinic… And Liftoff?
Here are the four keys to watch for when up-and-coming biotech Cue Biopharma (CUE) reports results today
CUE: It’s Deja Vu All Over Again
Cue Biopharma (CUE) might not be lighting up the newswires with major developments. Yet. But nearly every time management presents at a conference, the slide deck contains a new nugget (or two) of telling data. Yesterday’s appearance at the BIO CEO & Investor...
CUE: New Deck, New Data
The latest investor deck used at the JP Morgan Healthcare Conference reveals at least three new data points…
CUE: Old Perspectives, New Proof
Biotech stocks aren’t for the faint of heart. Forget crying, here’s why the recent volatility has me buying more…
CUE Lands $1 Billion Strategic Deal
Details, benefits and why the $1 billion strategic deal with LG Chem matters for CUE investors
